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Ventricular fibrillation (VF), the principle cause of sudden cardiac death,1,2 is largely resistant to ion channel–target-
ing antiarrhythmic drugs.3–6 The pathophysiology of ischemia 
(that mediates the adverse electrophysiological milieu)7 may 
represent a more promising target.
Clinical Perspective on p 1001
Animal studies have shown that early (phase I) VF arises 
during the first 30 minutes of ischemia when arrhythmogenic 
substances accumulate,8 but it remains unclear which sub-
stances are sufficient and necessary mediators of VF.8
Mediators may derive from ischemic myocytes and from 
other local tissue (including platelets). Thus, platelets may 
facilitate VF independently of their role in thrombus forma-
tion. Clinical trials suggest the mortality benefit of antiplate-
let agents, such as aspirin and αIIbβ3 integrin antagonists, may 
result from effects more complex than simple thrombus inhi-
bition.9–11 In animal studies, several platelet-activating fac-
tor antagonists12–14 reduced ischemia-induced VF incidence. 
Moreover, aspirin pretreatment reduced ischemia-induced VF 
in various animal models.15–17 However, there is a lack of evi-
dence directly linking anti-VF effects to platelet ablation. It 
has been argued that a systematic examination of the role of 
platelets in VF initiation during ischemia is long overdue.18
We have tested whether VF is facilitated by the activation 
of platelets trapped within the ischemic territory, resulting 
in the release of proarrhythmic secretome. A novel in vitro 
model system permitted myocardial ischemia to be induced 
in isolated rat hearts in the absence or presence of an autol-
ogous infusion of platelets. When ischemic zone (IZ) was 
made deliberately suboptimal, platelets facilitated the abil-
ity of ischemia to evoke VF, and secretome evoked VF in the 
absence of ischemia. Facilitation of VF was not attenuated by 
current clinical antiplatelet therapy.
Methods
Animals and Core Methods
Experiments were performed according to the United Kingdom 
Home Office Guide on the Operation of the Animals (Scientific 
Procedures) Act 1986. Heart perfusion, induction of ischemia, verifi-
cation and quantification of IZ size, and data recording and analysis 
were as described previously.19 Male Wistar rats (220–270 g) were 
anesthetized (pentobarbitone 60 mg/kg IP) and given sodium heparin 
250 IU IP. Blood samples (7–10 mL) for platelet preparation were 
© 2013 American Heart Association, Inc.
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Original Article
Background—We tested the hypothesis that ischemia-induced ventricular fibrillation (VF) is facilitated by platelets, trapped 
regionally in the ischemic zone and activated to release arrhythmogenic secretome.
Methods and Results—In a randomized study in blood-free, buffer-perfused isolated rat hearts, ischemic zone territory 
(34±1% of left ventricle) was selected so that ischemia evoked VF in only 42% of controls. VF incidence was increased 
to 91% (P<0.05) by coronary ligation–induced trapping of freshly prepared autologous platelets (infused before and 
during coronary ligation, with trapping confirmed by 111In-labeled platelet autoradiographic imaging). Trapping of 
platelet secretome prepared ex vivo, or platelet-sized fluorospheres, did not increase ischemia-induced VF incidence. 
Secretome alone did, however, evoke VF in 2 sham coronary-ligated hearts. Perfusion did not activate infused platelets 
in sham coronary-ligated hearts, whereas ligation activated trapped platelets (assessed by thromboxane release). In a 
separate study, trapping whole-heparinized blood mimicked the ability of trapped platelets to increase VF incidence. 
This effect was not prevented by >5 days oral pretreatment in vivo with clopidogrel (10 mg/kg per day) or indomethacin 
(2.4 mg/kg per day).
Conclusions—Platelets facilitate VF during acute ischemia independently of their ability to participate in occlusive thrombosis. 
Moreover, the effect is unresponsive to antiplatelet drugs commonly used. Labile secretome constituents appear to be 
responsible. This opens a novel avenue for antiarrhythmic drug research.  (Circ Arrhythm Electrophysiol. 2013;6:995-1001.)
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drawn by inferior vena caval puncture and collected into acid citrate 
dextrose buffer (120 mmol/L sodium citrate, 110 mmol/L glucose, 
80 mmol/L citric acid). Rats were then killed by cardiac excision, 
and hearts excised, immersed in cold (4ºC) Krebs solution (modi-
fied to contain 3 mEq/L K+ and 1.4 mEq/L Ca++), then cannulated for 
perfusion with similar Krebs solution (gased with 95% O2 plus 5% 
CO2) at 37ºC at a constant pressure (70 mm Hg). A silver electrogram (ECG) lead was positioned to impale a part of the anterior surface 
of the left ventricle that, from our experience, would be subserved 
by the artery to be occluded. The ECG was recorded (PowerLab; 
ADInstruments, United Kingdom) at a sampling rate of 2 kHz and 
with high- and low-pass frequency filters set at 0.3 Hz and 1 kHz. The 
standard definitions of rat ECG intervals were used.20 Experimental 
guiding principles and arrhythmia definitions were as described in the 
Lambeth Conventions.21 Coronary flow (CF) was measured by timed 
collection of coronary effluent. A silk suture (3/0 thread), sewn under 
the left main artery immediately after setup, was tightened to achieve 
regional ischemia, and the size of the IZ was determined at the end of 
perfusion using the disulphine blue method.19
Platelet Preparation and Control Groups
Washed platelets were derived by centrifugation, resuspended (2×108/
mL) in Krebs solution, then rested for ≥10 minutes before use. To 
validate platelet viability and aggregability when suspended in Krebs 
solution (the preparation method is validated only with Tyrode so-
lution), platelet aggregometry was performed22 using fibrillar type I 
horm collagen (Nycomed, Axis-Shield, United Kingdom), thrombin 
(Sigma, Poole, United Kingdom), and ADP (Sigma).
Three control groups were used in the first of 2 studies: plate-
let vehicle control solution (Krebs), fluorospheres, and secretome. 
The fluorosphere control group tested whether any increase in ar-
rhythmias in the platelet group was mediated by the mere presence 
of platelet-sized particles. The fluorospheres (Invitrogen, Paisley, 
United Kingdom) mimic platelet size and charge. Platelet secretome 
controls tested whether secretome facilitates ischemia-induced VF 
and whether secretome could evoke VF in the absence of ischemia. 
Secretome contains substances (eg, ATP, serotonin, histamine, and 
>300 proteins),23 many of which can alter cardiac electrophysiology.24 
To obtain secretome, the washed platelet pellet was resuspended in 4 
mL Krebs solution and stimulated with 1 U/mL thrombin. The ag-
gregated suspension was then centrifuged (1000g for 3 minutes) and 
the secretome collected.
Platelets, fluorospheres, and secretome were prepared in 4 mL of 
warmed, gased Krebs solution immediately before infusion and con-
tained 2×108/mL platelets, 4×109/mL fluorospheres, or (as quantified 
by Bradford assay) 0.21 mg/mL protein, respectively.
Platelet Delivery System
A Langendorff cannula was modified to allow infusion of washed 
platelets into the perfusate in a nonactivated and functional state 
(Figure 1). Platelets, platelet vehicle, fluorospheres, or secretome 
were delivered as infusion solutions to the cannula from polypropyl-
ene syringes attached to a syringe driver.
Experimental Design
In the first study, platelets were trapped in the IZ by coronary ligation. 
To validate the method, hearts were perfused with platelets radiola-
belled with 50 MBq 111In oxine sulfate. After coronary ligation, hearts 
were frozen in liquid nitrogen for autoradiography to be performed 
on 20-µm sections exposed to CL-XPosure Film (Thermo Fisher 
Scientific, Loughborough, United Kingdom) for 3 days. Then, 96 
rats were randomized into 8 groups: Krebs solution controls, washed 
platelets, platelet secretome or fluorospheres, each with coronary li-
gation or sham ligation. All hearts were perfused for 30 minutes with 
Figure 1. Novel cannula engineered for direct platelet delivery 
to the isolated heart. A modified Langendorff cannula was made 
from stainless steel and modified to receive a sidearm to allow 
passage of an inert 1-mm internal diameter polypropylene tube 
to the tip of the cannula. The shear rate within the sidearm tubing 
was subarteriolar (<1000/s).
A
B
C
D
E
Figure 2. Platelet aggregation studies confirm platelet viability 
and functionality. Washed rat platelets were derived by standard 
centrifugation and resuspended at a concentration of 2×108/
mL. Aggregation traces demonstrated normal dose–response 
curves to agonist stimulation with collagen, ADP, and thrombin in 
Tyrode solution (A–C) or Krebs solution (D and E). E, X refers to 
the time point at which 500 μL of washed platelets were perfused 
through the modification to the cannula at 100 μL/s. All traces 
are representative of n=3.
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Krebs solution, then infusion solution was delivered at 0.2 mL/min 
for 20 minutes, with coronary ligation (or sham ligation) performed 
at the half way point (10 minutes).
Thromboxane Assay
In separate groups of hearts, at the end of platelet infusion (after 
10-minute ischemia), the ligature was released and coronary efflu-
ent collected for 60 seconds. Thromboxane (TX) B2 was measured 
by ELISA assay (Biotrak thromboxane B2 enzyme immunoassay 
system; GE Healthcare, Amersham, United Kingdom). The TX mea-
sured is a marker of platelet activation and degranulation25 during 
ischemia and is not reperfusion-induced release, because true reper-
fusion-induced platelet adhesion and activation takes several minutes 
to manifest.26
Drug Administration and Blood Trapping
In a second study, an equivalent protocol was used to explore the 
ability of whole blood to mimic the ability of trapped platelets to 
facilitate ischemia-induced VF and to test the effects of standard an-
tiplatelet drugs. A blood sample was taken before cardiac excision, 
heparinized (0.1 U/mL), then delivered via the system used earlier 
(4 mL, >20 minutes, at a rate of 0.2 mL/min), with coronary liga-
tion and blood trapping performed half way through the infusion. 
Rats received PO indomethacin (n=14; 2.4 mg/kg per day; Sigma), 
clopidogrel (n=9; 10 mg/kg per day; Wockhardt, Wrexham, United 
Kingdom), or vehicle (n=20; 1 mL/kg per day of 4% v/v ethanol in 
distilled water) for a minimum of 5 consecutive days. The vehicle 
group was subdivided to provide blood-trapped (n=8) and blood-free 
(Krebs solution throughout; n=12) controls.
Exclusion Criteria
Based on previously published standards, hearts were excluded if 
preligation sinus heart rate (HR) was <200 beats/minute or CF was 
<5 mL/min,27 or if IZ was outside the range of 25% to 40% of total 
ventricular weight, or VF occurred before the onset of ischemia. VF 
susceptibility in individual hearts is not dependent on baseline HR 
or CF beyond these stated exclusion limits.27 Blood-perfused hearts 
were excluded if they developed an intracoronary thrombus before 
coronary ligation. The studies required 204 rats, of which 12 were 
excluded.
Statistical Analyses
Parametric variables (±SEM), including CF, HR, PR interval, QT 
interval at 90% repolarization (QT90),20 and light transmission for 
platelet aggregation, were evaluated by 1-way ANOVA and Dunnett 
test to compare treatments with control. Incidences of ventricular 
tachycardia and VF (dichotomous variables) were analyzed by Fisher 
exact test because of small sample sizes. This test was used for global 
multiple comparisons, and if significant, a pairwise comparison was 
performed versus controls using the same test. Other nonparametric 
variables were analyzed using the Steel–Dwass test, and the Kruskal–
Wallis test was used for the estimation of stochastic probability in 
intergroup comparisons. Probability values were 2-sided and results 
were deemed statistically significant when P<0.05. Statistical analy-
ses were performed on R, version 2.14.
Results
Delivered Platelets Were Viable and Functional
Aggregation traces demonstrated normal dose–response 
curves to agonists (Figure 2A–C), and 1 U/mL of thrombin 
induced a maximal aggregation response (Figure 2D). Washed 
platelets were nonactivated on exiting the delivery system 
setup without a heart attached, but could be fully activated by 
agonist stimulation (Figure 2E), validating the platelet deliv-
ery system and Krebs solution as a platelet vehicle.
Platelet Trapping Facilitates Ischemia-Induced VF
Coronary ligation trapped infused platelets within the IZ 
( Figure 3). Mean IZ values (33%–35%) were suboptimal for 
VF (Table 1), meaning that ischemia-induced VF occurred 
in only 42% of platelet-free controls as desired.28 Platelet 
trapping increased VF incidence to 91% (P<0.05), whereas 
trapping of secretome or fluorospheres had no such effect 
(Figure 4). Delivery of platelets in the absence of ischemia did 
not elicit VF (either in shams, or preischemia in hearts with 
Figure 3. The delivery of platelets is sufficient to cause platelet 
trapping. To validate the platelet delivery/trapping method, rat 
hearts were perfused with platelets radiolabelled with 50 MBq 
111In oxine sulfate. After coronary ligation, hearts were frozen in 
liquid nitrogen for autoradiography to be performed on 20-μm 
sections. Platelets were trapped by coronary ligation in the 
 ischemic zone (left ventricle, LV) and excluded (little adhesion) 
in the remote region (right ventricle, RV). Representative image 
of n=3.
Table 1. Baseline Characteristics of Hearts Subjected to Coronary Ligation
Baseline Variables 
(Value±SEM) Krebs Buffer (N=12) Platelet (N=11) Secretome (N=12) Fluorospheres (N=10) P Value
Heart rate, beats/min 264.4±8.9 278.5±8.9 280.1±12.4 287.0±13.3 0.89
Coronary flow, mL/min 10.1±0.7 9.7±0.7 10.0±0.7 10.7±0.6 0.73
PR interval, ms 38.2±1.2 39.7±2.4 37.6±0.8 39.2±1.8 0.82
QT90 interval, ms 53.3±1.8 48.5±2.3 55.2±2.2 52.3±1.9 0.59
IZ, % of ventricular mass 34.1±0.8 33.0±0.7 34.2±1.0 34.6±0.8 0.64
IZ indicates ischemic zone.
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coronary ligation). However, 2 sham coronary-ligated hearts 
experienced VF during secretome infusion.
Hemodynamic and ECG Variables in Platelet 
Trapping Study
Baseline HR, CF, PR, and QT90 intervals did not differ 
between the 4 groups (Table 2) here (and elsewhere in the 
study). Coronary ligation evoked changes typical for the 
model, such as a fall in CF. There were no significant differ-
ences in CF or PR between groups at any time. The QT90 
interval in coronary-ligated controls increased during isch-
emia from 53±2 to 68±3 ms, then gradually fell toward the 
end of the experiment to 61±3 ms, as seen previously with 
this model.19,20,29 QT90 changes were similar with platelet 
trapping, but the increase was significantly greater versus the 
other groups 30 minutes after the onset of ischemia (plate-
let, 71±4 ms; control, 61±3 ms; secretome, 64±4 ms; fluoro-
spheres, 59±4 ms; P<0.05). In sham ligation controls, there 
were no significant effects of platelet or secretome infusion on 
CF, PR, or QT90. The only HR variation between groups was 
a transient increase at the start of secretome infusion in sham 
(Figure 5A) and coronary-ligated hearts (Figure 5B) with a 
weaker (nonsignificant) trend toward an increase in hearts 
with platelets trapped by ligation (Figure 5B).
Regional Ischemia Activates Platelets
In Krebs solution–perfused control hearts subjected to coro-
nary ligation, no TX was detected in coronary effluent. How-
ever, in hearts with platelets trapped in the IZ, a substantial 
amount of TX was detected (Figure 6).
Drug Pretreatment Action on Platelets, VF, and 
Hemodynamics
Oral pretreatment with antiplatelet agents inhibited (but did not 
abolish) ex vivo aggregation responses to ADP (Figure 7A) and 
thrombin (Figure 7B). CF, HR, PR interval, QT90 interval, and 
IZ size were similar to values in the platelet trapping study and 
did not vary significantly between groups (Table 3). Ischemia-
induced VF was facilitated by blood trapping compared with 
blood-free controls (P<0.05; Figure 8). Facilitation of VF was 
not reduced significantly by pretreatment in vivo with clopido-
grel (P>0.05) or indomethacin (P>0.05; Figure 8).
Discussion
Overview
Platelets trapped in the IZ by coronary ligation became acti-
vated by ischemia, resulting in an increase in VF incidence in 
hearts in which VF risk would ordinarily be low due to sub-
optimal ischemia (small IZ). Platelets were arrhythmogenic 
only when trapped in the IZ. Trapping of autologous whole 
blood mimicked the platelet effect. This was not prevented by 
in vivo pretreatment with clopidogrel or indomethacin (which 
reduced platelet aggregability). Platelets, platelet trapping, 
and secretome did not lower CF, precluding the possibility 
that platelets induced VF by evoking ischemia or rendering 
it more severe. This is, therefore, the first direct evidence that 
platelets facilitate VF during ischemia independently of their 
role in thrombosis.
Platelets and the Pathophysiological Reserve for VF
Previous reports on platelet involvement in VF are contradic-
tory. Pretreatment with aspirin, ticlopidine, meclofenamate, 
or indomethacin reduced ischemia-induced VF incidence 
from a high baseline in anesthetized rats.15,16 However, aspirin 
failed to reduce ischemia-induced VF in conscious rats with 
a large IZ.30 Likewise, platelet-activating factor antagonists 
ameliorated ischemia-induced VF in vivo in 2 study,31 but not 
in others.32,33 Moreover, platelet-activating factor and platelet-
activating factor antagonists possess platelet-independent 
effects on ischemia-induced VF.28
In most published studies, the IZ was not determined. It is 
well established that when the IZ is large in vivo and even in 
Krebs solution–perfused rat hearts, all controls develop VF 
due to pathophysiological reserve.19,20,34 A pathophysiologi-
cal reserve precludes identification of individual mediators 
of VF. In the present study, the pathophysiological reserve 
was reduced by making IZ suboptimal, thereby revealing 
the pathophysiological ability of trapped platelets to facili-
tate ischemia-induced VF. The question remaining is to 
Figure 4. Platelet trapping facilitates ischemia-induced ventricu-
lar fibrillation (VF). Incidence of VF evoked by 30-min regional 
ischemia in the Langendorff-perfused rat heart. Platelets, secre-
tome, or fluorospheres were delivered for 20 min beginning 10 
min before the start of ischemia. *P<0.05 vs controls.
Table 2. Baseline Characteristics of Sham Hearts in the Platelet-Trapping Study
Baseline Variables 
(Value±SEM) Krebs Buffer (N=11) Platelet (N=12) Secretome (N=11) Fluorospheres (N=11) P Value
Heart rate, beats/min 285.8±14.5 296.3±12.6 295.5±12.5 277.0±14.7 0.81
Coronary flow, mL/min 9.5±0.8 9.0±0.9 9.0±0.8 9.6±0.5 0.69
PR interval, ms 40.4±1.4 35.6±1.3 39.6±1.4 39.8±1.3 0.78
QT90 interval, ms 56.5±3.2 56.5±1.7 55.1±1.9 52.1±2.9 0.63
Dhanjal et al  Platelets and Ventricular Fibrillation  999
what extent does this knowledge inform better drug target-
ing of VF?
Mechanistic Insights
The increase in QT90 interval in hearts with platelets trapped 
in the IZ resonates with data from De Jong and Dekker18 who 
exposed human platelet secretome to rabbit cardiomyocytes 
and observed action potential duration prolongation and after-
depolarizations. However, other findings provide better clues 
to mechanisms.
Platelets were inert in nonischemic hearts, so the mecha-
nism of VF facilitation required an interaction with compo-
nents of the ischemic milieu. Additionally, platelet-sized 
fluorospheres were not arrhythmogenic (in shams or when 
trapped by ligation), confirming that VF facilitation by plate-
lets does not operate by simple physical presence.
Trapped platelets released TX in the present study. 
Moreover, in 2 sham hearts (no ischemia), exogenously 
administered secretome caused VF. In our historical database 
of n>200 controls, otherwise normal hearts do not exhibit 
spontaneous VF. The mechanism was primary, because secre-
tome did not induce ischemia (no reduction in CF) in shams. 
The secretome effect in shams contrasts with the lack of plate-
let and blood effects. Conversely, secretome had little effect 
when trapped in the IZ, in sharp contrast to the facilitation of 
VF by trapped platelets and blood.
These observations provide coherent mechanistic insight: 
ischemia activates trapped platelets to release secretome con-
taining a labile and short-lived arrhythmogenic mediator, suf-
ficient to facilitate VF when IZ is suboptimal. It is important to 
emphasize that these mechanistic insights are tentative.
Clinical Relevance
Due to the complex interaction between platelets and other 
blood components, we modified our platelet-trapping 
Figure 5. Secretome infusion resulted in fluctuations in heart 
rate (HR). Rat platelet secretome (0.21 mg/mL protein) in a final 
volume of 4 mL warmed, gased Krebs solution was delivered at 
0.2 mL/min for 20 min, with coronary ligation (or sham ligation) 
performed at the half way point (10 min). Secretome consistently 
increased HR (defined as any change sustained for ≥10 sec) 
compared with the maximum changes during the equivalent time 
interval in other groups of sham (A) or coronary-ligated (B) hearts. 
*P<0.05 vs controls.
Figure 6. Regional ischemia activates platelets. Rat hearts under-
went 10-min ischemia or sham ligation. In 2 groups, platelets 
were delivered for 20 min beginning 10 min before the start of 
ischemia or sham ligation. Thromboxane B2 was measured by 
ELISA in the coronary effluent collected during the first minute 
after cessation of infusion of platelets (ligation or sham). *P<0.05 
vs Krebs ligation (no platelets).
Figure 7. Effects of drug pretreatment on platelet aggregation. 
Rats were pretreated with indomethacin or clopidogrel for a 
minimum of 5 days. Washed platelets were derived by standard 
centrifugation and resuspended in Krebs solution at 2×108/mL. 
Platelet aggregation responses to (A) ADP (n=3) and (B) thrombin 
(n=3) are shown. *P<0.05 vs controls.
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approach to examine whether standard antiplatelet drugs 
administered in vivo could reduce the ability of trapped whole 
blood to facilitate VF in vitro. Clopidogrel and indomethacin 
were not effective in this regard. Clopidogrel reduces plate-
let P-selectin expression, but does not prevent platelets from 
secreting α-granular contents; indomethacin inhibits cyclo-
oxygenase, but is not selective for TX synthesis.35,36 Moreover, 
despite high dosage, the effect of each drug on responses to 
platelet activators in vitro, although significant, was not sub-
stantial. Thus, standard antiplatelet drugs are unable to affect 
ischemia-trapped platelet function sufficiently to block facili-
tation of VF. This agrees with their lack of benefit against sud-
den cardiac death in humans.
Limitations
The isolated perfused unloaded rat heart exhibits ischemic VF, 
which is not subject to normal mechanical or autonomic influ-
ences. Confidence that present findings have clinical relevance 
is limited by the extent to which the lack of loading and intact 
innervation may change the ability of platelets to facilitate 
ischemia-induced VF in suboptimal ischemia. To test this, in 
vivo experimentation will be required.
Future Work
There are a large number of constituents of the platelet secretome, 
and identification of the one(s) necessary for facilitation of VF 
is beyond the scope of the present study. TXA2 is a noteworthy 
labile and short-lived constituent. In addition to our evidence 
of ischemia-specific TX release from platelets trapped in the 
IZ, studies with the TX synthase blockers, UK38485, R-68070, 
and U-63557A,25,37 suggest that TXA2 may facilitate ischemia-
induced VF in vivo. Together, this justifies future work to clarify 
links between the platelet, TX, and ischemia-induced VF.
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IZ indicates ischemic zone.
Figure 8. Incidence of ventricular fibrillation (VF) in antiplate-
let drug pretreated study. Incidence of VF evoked by 30-min 
regional ischemia in the Langendorff-perfused rat heart. Rats 
were pretreated for ≥5 days in vivo with drug or vehicle. Autolo-
gous blood was delivered for 20 min beginning 10 min before the 
start of ischemia. Blood trapping was associated with a high inci-
dence of VF (*P<0.05 vs control hearts without blood trapping). 
VF incidence with blood trapping was not significantly reduced 
by clopidogrel or indomethacin pretreatment in vivo.
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CLInICAL PERSPECTIVE
Acute myocardial ischemia (MI) may result in ventricular fibrillation (VF) and sudden death, often with a brief interlude 
between MI onset and death (hence the out-of-hospital prevalence), confirmed as ≈5 to 20 minutes by numerous animal 
model studies. This brief interlude necessitates pretreatment of those at risk. Unfortunately, available drugs are limited in 
utility due to safety or efficacy issues. New approaches/targets are needed. Animal studies show that the MI region produces 
or accumulates numerous pathological mediators that may facilitate ischemia-induced VF. Using blood-free perfused rat 
hearts, we made ischemic territory sufficiently small (34±1% of left ventricle) to evoke VF in only 42% of controls. Impor-
tantly, VF incidence was increased to 91% (P<0.05) by coronary ligation–induced trapping of freshly prepared autologous 
platelets (trapping confirmed by 111In-labeled platelet autoradiographic imaging) without any change in ischemic territory. 
The trapped platelets released thromboxane, a component of platelet secretome. Freshly prepared secretome evoked VF in 
2 nonischemic hearts. Trapping autologous whole heparinized blood mimicked the ability of trapped platelets to increase 
VF incidence. The effect was not prevented by >5 days oral pretreatment in vivo with clopidogrel (10 mg/kg per day) or 
indomethacin (2.4 mg/kg per day). This is the first evidence that platelets facilitate VF during acute MI independently of their 
ability to participate in occlusive thrombosis. Moreover, because the effect is unresponsive to commonly used antiplatelet 
drugs, we propose that platelet secretome (its release or its receptor-mediated actions) represents a new target for drug dis-
covery in acute MI, for much sought prophylaxis against VF-related sudden death.
